Mentari Therapeutics publishes pro forma combined financial statements with InMed Pharmaceuticals
MTRI•MTRI•MTRI•MTRI•Mentari Therapeutics published pro forma financial statements reflecting its merger with InMed Pharmaceuticals, which closed November 6, 2026. The statements show $478.12 million in cash as of June 30, 2026, and a $37.29 million net loss from continuing operations for the first half of 2026.
The combined statements report $478.12 million in cash and $478.78 million in total assets against $11.42 million in liabilities as of June 30, 2026. The cash figure reflects $490 million in pre-closing financing, including convertible notes. Net loss from continuing operations was $37.29 million for the six months ended June 30, 2026, with research spending of $31.1 million. For 2025, net loss from continuing operations was $26.9 million and operating expenses were $27.54 million.
